- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04595487
LVSP vs RVP in Patients With AV Conduction Disorders (LEAP)
Permanent Left Ventricular Septal Pacing Versus Right Ventricular Pacing in Patients With Atrioventricular Conduction Disorders: a Randomized Trial: LEAP Trial
Rationale:
Permanent cardiac pacing is the only available therapy in patients with atrioventricular (AV) conduction disorders and can be life-saving. Right ventricular pacing (RVP), the routine clinical practice for decades in these patients, is non-physiologic, leads to dyssynchronous electrical and mechanical activation of the ventricles, and may cause pacing-induced cardiomyopathy and heart failure.
Left ventricular septal pacing (LVSP) is an emerging form of physiologic pacing that can possibly overcome the adverse effects of RVP.
Study design and hypotheses:
The LEAP trial is a multi-center investigator-initiated, prospective, randomized controlled, open label, blinded endpoint evaluation (PROBE) study that compares LVSP with conventional RVP. A total of four hundred seventy patients with a class I or IIa indication for pacemaker implantation due to AV conduction disorders and an expected ventricular pacing percentage >20% will be randomized 1:1 to LVSP or RVP. The primary endpoint is a composite endpoint of all-cause mortality, hospitalization for heart failure and a more than 10% decrease in left ventricular ejection fraction (LVEF) in absolute terms leading to a LVEF below 50% at one year follow-up. LVSP is anticipated to result in improved outcomes.
Secondary objectives are to evaluate whether LVSP is cost-effective and associated with an improved quality of life (QOL) as compared to RVP. Quality of life is expected to improve with LVSP and reduced healthcare resource utilizations are expected to ensure lower costs in the LVSP group during follow-up, despite initial higher costs of the implantation.
Study design: Multi-center investigator-initiated, prospective, randomized controlled, open label, blinded endpoint evaluation (PROBE) study.
Study population: Adult patients with a bradycardia-pacing indication because of AV conduction disorders with an expected ventricular pacing percentage of ≥ 20% and a left ventricular ejection fraction (LVEF) >/= 40%. Four hundred seventy patients will be randomized 1:1 to LVSP or RVP.
Intervention: LVSP vs RVP.
Main study parameters/endpoints:
The primary endpoint is a composite of all-cause mortality, hospitalization for heart failure, and a more than 10% point decrease in left ventricular ejection fraction (LVEF) leading to an LVEF below 50%, which as a binary combined endpoint will be determined at one year follow-up.
Secondary endpoints are:
- Time to first occurrence of all cause mortality or hospitalization for heart failure.
- Time to first occurrence of all cause mortality.
- Time to first occurrence of hospitalization for heart failure.
- Time to first occurrence of atrial fibrillation (AF) de novo.
- The echocardiographic changes in LVEF at one year.
- The echocardiographic changes in diastolic (dys-)function at one year.
- The occurrence of pacemaker related complications.
- Quality of life (QOL), cost-effectiveness analyses (CEA) and budget impact analysis (BIA).
The secondary endpoints (other than echocardiographic LVEF change) will be determined at the end of the follow-up period, when the last included patient has reached one year follow-up. The individual follow-up time for patients at this time point will vary with a minimum of one year.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Justin Luermans, MD PhD
- Phone Number: +31433875093
- Email: justin.luermans@mumc.nl
Study Locations
-
-
-
Genk, Belgium
- Not yet recruiting
- Ziekenhuis Oost Limburg
-
Contact:
- Wilfried Mullens, MD, PhD
-
Gent, Belgium
- Not yet recruiting
- University Hospital Gent
-
Contact:
- Jan de Pooter, MD, PhD
-
-
-
-
-
Praha, Czechia
- Recruiting
- University Hospital Kralovske Vinohrady
-
Contact:
- Karol Curila, MD, PhD
-
-
-
-
-
Rome, Italy
- Not yet recruiting
- Policlinico Casilino
-
Contact:
- Domenico Grieco, MD, PhD
-
-
-
-
-
Alkmaar, Netherlands
- Recruiting
- Noordwest Ziekenhuisgroep
-
Contact:
- Stefan Timmer, MD, PhD
-
Delft, Netherlands
- Recruiting
- Reinier de Graaf Gasthuis
-
Contact:
- Arnaud Hauer, MD, PhD
-
Eindhoven, Netherlands
- Recruiting
- Catharina Ziekenhuis
-
Contact:
- Nard Rademakers, MD, PhD
-
Enschede, Netherlands
- Recruiting
- Medisch Spectrum Twente
-
Contact:
- Jurren van Opstal, MD, PhD
-
Nieuwegein, Netherlands
- Recruiting
- Sint Antonius Ziekenhuis
-
Contact:
- Vincent van Dijk, MD, PhD
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 ER
- Recruiting
- Maastricht University
-
Contact:
- Justin Luermans, PhD
- Email: justin.luermans@mumc.nl
-
-
-
-
-
Kraków, Poland
- Not yet recruiting
- University Hospital Jaegellonian
-
Contact:
- Marek Jastrzebski, MD, PhD
-
-
-
-
-
Valencia, Spain
- Not yet recruiting
- Hospital Universitario y Politecnico La Fe
-
Contact:
- Óscar Cano Pérez, MD, PhD
-
-
-
-
-
Geneva, Switzerland
- Not yet recruiting
- University Hospital of Geneva
-
Contact:
- Haran Burri, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18y
- Life expectancy with good functional status of > 1y
Class I or IIa pacemaker indication due to AV conduction disorder
- Acquired 3rd or 2nd degree AVB
- Atrial arrhythmia with slow ventricular conduction
- Expected ventricular pacing percentage > 20%
- LVEF >/= 40%
- Signed and dated informed consent form
Exclusion Criteria:
- HF NYHA class III-IV
- Class I indication for CRT
- Class I indication for ICD
- Previous implanted CIED (except for ILR)
- Atrial arrhythmia with planned AV junction ablation
- PCI or CABG <30 days before enrollment
- Valvular heart disease with indication for valve repair or replacement
- Hypertrophic cardiomyopathy with interventricular septum thickness > 2 cm
- Renal insufficiency requiring hemodialysis
- Active infectious disease or malignancy
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: left ventricular septal pacing
Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
|
In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology. In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion. |
Active Comparator: right ventricular pacing
Implantation of a pacemaker with the ventricular lead placed in the RV.
|
In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binary combined endpoint consisting of all-cause mortality, hospitalization for heart failure, and a more than 10% point decrease in left ventricular ejection fraction (LVEF) leading to a LVEF below 50%.
Time Frame: Determined at one year follow-up
|
Hospitalization for heart failure is defined as:
All-cause mortality is defined as death from any cause and subdivided into cardiovascular and non-cardiovascular death. |
Determined at one year follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first occurrence of hospitalization for heart failure.
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Hospitalization for heart failure is defined as:
|
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Time to first occurrence of all cause mortality.
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
All-cause mortality is defined as death from any cause and subdivided into cardiovascular and non-cardiovascular death.
|
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Time to first occurrence of all cause mortality or hospitalization for heart failure.
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
All cause mortality and hospitalization for heart failure are defined as mentioned in secondary outcome 1 and 2.
|
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Time to first occurrence of atrial fibrillation (AF) de novo.
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Occurrence of atrial fibrillation de novo is defined as: Occurrence of a first clinical or subclinical episode of AF as diagnosed respectively by ECG (clinical AF) or by pacemaker interrogation (subclinical AF/atrial high rate episode, lasting > 24 hours) in patients without a history of AF. |
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
The echocardiographic changes in left ventricular ejection fraction (LVEF) at one year.
Time Frame: Determined at one year follow-up
|
Change in LVEF is based on echocardiography at one year follow-up as compared to baseline echocardiography.
|
Determined at one year follow-up
|
The echocardiographic changes in diastolic (dys-)function at one year.
Time Frame: Determined at one year follow-up
|
Diastolic function will be assessed by determining the following echocardiographic parameters at baseline and one year follow-up: E-wave, A-wave, E/A ratio, e' septal and lateral, E/e', 2D-strain of the left ventricle and atrium, pressure gradient across the tricuspid valve (dPTI) and volume of the left-atrium (LAVI).
Diastolic function will be graded according to the current guidelines.
|
Determined at one year follow-up
|
The occurrence of pacemaker related complications.
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Pacemaker (implantation) related complications occurring during pacemaker implantation or during follow-up after pacemaker implantation consisting of: pneumothorax; cardiac tamponade; pocket hematoma requiring re-intervention; pacemaker infection; lead luxation, dislocation, or perforation requiring re-intervention; pacemaker and lead dysfunction during follow-up (elevated threshold/sensing issues/early battery depletion) requiring re-intervention.
|
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Quality of Life analysis reported as Quality Adjusted Life Years (QALYs)
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Quality of life will be analyzed using the EQ-5D-5L questionnaire at baseline, 6 and 12 months follow-up and every 6 months thereafter.
|
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Cost effectiveness analysis (CEA)
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
A trial based economical evaluation from a societal perspective will be performed in accordance with the Dutch guidelines for economical evaluations in healthcare. Resource use will be measured from a societal perspective using data from case record forms and the Medical Consumption (MCQ) and Productivity loss (PCQ) questionnaires. |
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Budget Impact Analysis (BIA)
Time Frame: Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Budget impact analysis will be performed from a societal, health care provider and health care insurer perspective. The eligible population will be estimated based on national health care data. Costs of the intervention and heart failure costs will be included. Indirect costs will not be included. The time horizon will be 3 years. The expected uptake rate will be estimated based on a panel of experts (cardiologists, implementation specialist, patient representatives) and analyses will be performed for this expected uptake rate and several slightly higher and lower uptake rates. Uncertainties and scenarios will be discussed in a panel of experts as well and different scenarios will be analysed. Recommendations of the ISPOR task force are followed for all BIA calculations. |
Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Justin Luermans, MD PhD, Department of cardiology
- Principal Investigator: Kevin Vernooy, MD PhD, Department of cardiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL72047.068.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrioventricular Block
-
University Hospital of FerraraRecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Left Bundle-Branch Block | Bundle-Branch Block | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Atrioventricular Block | Heart Failure, Systolic | Ventricular Arrythmia | Heart Failure,Congestive | Bradyarrhythmia | Heart Arrhythmia | Reduced... and other conditionsItaly
-
University of Sao PauloUnknownCongenital Complete Atrioventricular Heart Block | High Grade Atrioventricular Block | Postoperative Complete Heart BlockBrazil
-
Tongji HospitalGuangdong Provincial People's Hospital; Wuhan Asia Heart Hospital; Fu Wai Hospital... and other collaboratorsUnknownBradycardia | Sick Sinus Syndrome | High Degree Second Degree Atrioventricular Block | Complete Atrioventricular BlockChina
-
Tongji HospitalGuangdong Provincial People's Hospital; Wuhan Asia Heart Hospital; Fu Wai Hospital... and other collaboratorsUnknownBradycardia | Sick Sinus Syndrome | Complete Atrioventricular Block | High Degree Second Degree Atrioventricular Block (Disorder)China
-
Gianluca BottoUnknownFirst Degree Atrioventricular BlockItaly
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrioventricular Conduction BlockUnited States, Belgium, Hong Kong, Malaysia, Spain, Austria, Denmark, France
-
West China HospitalRecruitingAVB - Atrioventricular BlockChina
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrioventricular Conduction BlockDenmark, United States, Belgium, Italy, Malaysia, Spain, France, Austria, Czechia
-
Quovadis AssociazioneRecruitingSinus Node Disease | Atrioventricular; Block, Second Degree (Types I and II)Italy
-
NYU Langone HealthRecruitingAVB - Atrioventricular Block | Fetal AVBUnited States, Canada
Clinical Trials on Left ventricular septal pacing
-
Fu Wai Hospital, Beijing, ChinaNot yet recruitingHeart Failure | Cardiac Resynchronization Therapy | Left Ventricular Septal Pacing | Right Ventricular Septal PacingChina
-
Main Line HealthMedtronic; Sharpe-Strumia Research FoundationRecruitingAortic Valve Stenosis | Complete Heart Block | High Degree Second Degree Atrioventricular Block | Pacemaker-Induced CardiomyopathyUnited States
-
Abbott Medical DevicesCompleted
-
University Hospital, BordeauxMinistry of Health, FranceUnknownHeart Failure | Coronary Disease | Cardiomyopathy, DilatedFrance
-
National and Kapodistrian University of AthensNot yet recruitingHeart Failure With Reduced Ejection FractionGreece
-
First Affiliated Hospital of Wenzhou Medical UniversityShanghai Zhongshan Hospital; Shanghai 10th People's Hospital; The Affiliated... and other collaboratorsNot yet recruitingHeart Failure | Atrioventricular Block, Second and Third Degree | Left Bundle Branch PacingChina
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart FailureUnited Kingdom, France, Canada, Belgium, Hungary, Italy, Netherlands
-
The First Affiliated Hospital with Nanjing Medical...Xijing Hospital; Zhongshan Hospital Xiamen University; Shanghai Zhongshan Hospital and other collaboratorsRecruitingAtrioventricular BlockChina
-
Catharina Ziekenhuis EindhovenWithdrawnHeart FailureNetherlands
-
Yonsei UniversityNot yet recruitingAtrioventricular Block | Left Bundle Branch Area Pacing | BradyarrhythmiaKorea, Republic of